Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""compounds 4"" wg kryterium: Temat


Tytuł :
Chiral HPLC separation of enantiomeric blebbistatin derivatives and racemization analysis in vertebrate tissues.
Autorzy :
Suthar SK; Printnet Limited, Kisgömb utca 25-27, 1135, Budapest, Hungary; MTA-ELTE Motor Pharmacology Research Group, Pázmány Péter sétány 1/C, 1117, Budapest, Hungary.
Rauscher AÁ; MTA-ELTE Motor Pharmacology Research Group, Pázmány Péter sétány 1/C, 1117, Budapest, Hungary; Motorpharma Ltd., Szilágyi Erzsébet fasor 27, 1026, Budapest, Hungary.
Winternitz M; MTA-ELTE Motor Pharmacology Research Group, Pázmány Péter sétány 1/C, 1117, Budapest, Hungary; Department of Biochemistry, Eötvös Loránd University, Pázmány Péter sétány 1/C, 1117, Budapest, Hungary.
Gyimesi M; MTA-ELTE Motor Pharmacology Research Group, Pázmány Péter sétány 1/C, 1117, Budapest, Hungary; Motorpharma Ltd., Szilágyi Erzsébet fasor 27, 1026, Budapest, Hungary; Department of Biochemistry, Eötvös Loránd University, Pázmány Péter sétány 1/C, 1117, Budapest, Hungary.
Málnási-Csizmadia A; MTA-ELTE Motor Pharmacology Research Group, Pázmány Péter sétány 1/C, 1117, Budapest, Hungary; Motorpharma Ltd., Szilágyi Erzsébet fasor 27, 1026, Budapest, Hungary; Department of Biochemistry, Eötvös Loránd University, Pázmány Péter sétány 1/C, 1117, Budapest, Hungary. Electronic address: .
Pokaż więcej
Źródło :
Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2021 Sep 10; Vol. 204, pp. 114246. Date of Electronic Publication: 2021 Jul 06.
Typ publikacji :
Journal Article
MeSH Terms :
Heterocyclic Compounds, 4 or More Rings*
Vertebrates*
Animals ; Chromatography, High Pressure Liquid ; Rats ; Stereoisomerism
Czasopismo naukowe
Tytuł :
Pancracine, a Montanine-Type Amaryllidaceae Alkaloid, Inhibits Proliferation of A549 Lung Adenocarcinoma Cells and Induces Apoptotic Cell Death in MOLT-4 Leukemic Cells.
Autorzy :
Koutová D; Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Republic.
Havelek R; Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Republic.
Peterová E; Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Republic.
Muthná D; Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Republic.
Královec K; Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentska 573, 532 10 Pardubice, Czech Republic.
Breiterová K; ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
Cahlíková L; ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
Řezáčová M; Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Republic.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Jun 29; Vol. 22 (13). Date of Electronic Publication: 2021 Jun 29.
Typ publikacji :
Journal Article
MeSH Terms :
Adenocarcinoma of Lung/*pathology
Cell Proliferation/*drug effects
Heterocyclic Compounds, 4 or More Rings/*pharmacology
Leukemia/*pathology
Lung Neoplasms/*pathology
A549 Cells ; Alkaloids/isolation & purification ; Alkaloids/pharmacology ; Amaryllidaceae/chemistry ; Antineoplastic Agents, Phytogenic/isolation & purification ; Antineoplastic Agents, Phytogenic/pharmacology ; Apoptosis/drug effects ; Cell Line, Tumor ; Hep G2 Cells ; Heterocyclic Compounds, 4 or More Rings/isolation & purification ; Humans ; MCF-7 Cells
Czasopismo naukowe
Tytuł :
Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor.
Autorzy :
Nishiya N; Division of Integrated Information for Pharmaceutical Sciences, Department of Clinical Pharmacy, Iwate Medical University School of Pharmacy, Yahaba, Japan.
Oku Y; Division of Integrated Information for Pharmaceutical Sciences, Department of Clinical Pharmacy, Iwate Medical University School of Pharmacy, Yahaba, Japan.
Ishikawa C; Division of Integrated Information for Pharmaceutical Sciences, Department of Clinical Pharmacy, Iwate Medical University School of Pharmacy, Yahaba, Japan.
Fukuda T; Division of Chemistry and Materials Science, Graduate School of Engineering, Nagasaki University, Nagasaki, Japan.
Dan S; Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
Mashima T; Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
Ushijima M; Clinical Research and Medical Development Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Furukawa Y; Division of Integrated Information for Pharmaceutical Sciences, Department of Clinical Pharmacy, Iwate Medical University School of Pharmacy, Yahaba, Japan.
Sasaki Y; Division of Integrated Information for Pharmaceutical Sciences, Department of Clinical Pharmacy, Iwate Medical University School of Pharmacy, Yahaba, Japan.
Otsu K; Division of Developmental Biology and Regenerative Medicine, Department of Anatomy, Iwate Medical University, Yahaba, Japan.
Sakyo T; Division of Integrated Information for Pharmaceutical Sciences, Department of Clinical Pharmacy, Iwate Medical University School of Pharmacy, Yahaba, Japan.
Abe M; Division of Integrated Information for Pharmaceutical Sciences, Department of Clinical Pharmacy, Iwate Medical University School of Pharmacy, Yahaba, Japan.
Yonezawa H; Division of Integrated Information for Pharmaceutical Sciences, Department of Clinical Pharmacy, Iwate Medical University School of Pharmacy, Yahaba, Japan.
Ishibashi F; Division of Marine Life Science and Biochemistry, Graduate School of Fisheries and Environmental Sciences, Nagasaki University, Nagasaki, Japan.
Matsuura M; Teikyo University Graduate School of Public Health, Tokyo, Japan.
Tomida A; Division of Genome Research, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
Seimiya H; Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
Yamori T; Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
Iwao M; Division of Chemistry and Materials Science, Graduate School of Engineering, Nagasaki University, Nagasaki, Japan.
Uehara Y; Division of Integrated Information for Pharmaceutical Sciences, Department of Clinical Pharmacy, Iwate Medical University School of Pharmacy, Yahaba, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2021 May; Vol. 112 (5), pp. 1963-1974. Date of Electronic Publication: 2021 Mar 24.
Typ publikacji :
Journal Article
MeSH Terms :
Heterocyclic Compounds, 4 or More Rings/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Acrylamides/pharmacology ; Aniline Compounds/pharmacology ; Animals ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Drug Resistance, Neoplasm/genetics ; Drug Screening Assays, Antitumor/methods ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Gene Expression ; Heterocyclic Compounds, 4 or More Rings/chemistry ; Heterografts ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/metabolism ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Molecular Targeted Therapy ; Mollusca/chemistry ; Mutagenesis, Site-Directed ; Mutation ; Protein Kinase Inhibitors/chemistry
Czasopismo naukowe
Tytuł :
p300/CBP inhibitor A-485 inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss.
Autorzy :
Huo S; Department of Bone and Joint Surgery, Department of Orthopedics, Renji Hospital, School of Medicine, Shanghai Jiaotong University, China.
Liu X; Department of Ultrasound, Renji Hospital, School of Medicine, Shanghai Jiaotong University, China.
Zhang S; Department of Bone and Joint Surgery, Department of Orthopedics, Renji Hospital, School of Medicine, Shanghai Jiaotong University, China.
Lyu Z; Department of Bone and Joint Surgery, Department of Orthopedics, Renji Hospital, School of Medicine, Shanghai Jiaotong University, China.
Zhang J; Department of Bone and Joint Surgery, Department of Orthopedics, Renji Hospital, School of Medicine, Shanghai Jiaotong University, China.
Wang Y; Department of Bone and Joint Surgery, Department of Orthopedics, Renji Hospital, School of Medicine, Shanghai Jiaotong University, China.
Nie B; Department of Bone and Joint Surgery, Department of Orthopedics, Renji Hospital, School of Medicine, Shanghai Jiaotong University, China. Electronic address: .
Yue B; Department of Bone and Joint Surgery, Department of Orthopedics, Renji Hospital, School of Medicine, Shanghai Jiaotong University, China. Electronic address: .
Pokaż więcej
Źródło :
International immunopharmacology [Int Immunopharmacol] 2021 May; Vol. 94, pp. 107458. Date of Electronic Publication: 2021 Feb 21.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Density Conservation Agents/*therapeutic use
Bone Resorption/*drug therapy
E1A-Associated p300 Protein/*antagonists & inhibitors
Heterocyclic Compounds, 4 or More Rings/*therapeutic use
Membrane Proteins/*antagonists & inhibitors
Osteoclasts/*drug effects
Osteoporosis/*drug therapy
Phosphoproteins/*antagonists & inhibitors
Animals ; Bone Density Conservation Agents/pharmacology ; Cell Differentiation/drug effects ; Cell Line ; Female ; Heterocyclic Compounds, 4 or More Rings/pharmacology ; Mice, Inbred C57BL ; Osteoclasts/physiology ; Ovariectomy ; Rats
Czasopismo naukowe
Tytuł :
Improved Inhibitory and Absorption, Distribution, Metabolism, Excretion, and Toxicology (ADMET) Properties of Blebbistatin Derivatives Indicate That Blebbistatin Scaffold Is Ideal for drug Development Targeting Myosin-2.
Autorzy :
Gyimesi M; Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.).
Rauscher AÁ; Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.).
Suthar SK; Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.).
Hamow KÁ; Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.).
Oravecz K; Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.).
Lőrincz I; Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.).
Borhegyi Z; Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.).
Déri MT; Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.).
Kiss ÁF; Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.).
Monostory K; Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.).
Szabó PT; Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.).
Nag S; Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.) .
Tomasic I; Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.).
Krans J; Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.).
Tierney PJ; Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.).
Kovács M; Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.).
Kornya L; Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.) .
Málnási-Csizmadia A; Department of Biochemistry, Eötvös Loránd University, Budapest and Martonvásár, Hungary (M.G., K.O., I.L., Z.B., M.K., A.M.-C.); MTA-ELTE Motor Pharmacology Research Group, Budapest, Hungary (M.G., M.K., A.M.-C.); Motorharma Ltd., Budapest, Hungary (A.Á.R.); Printnet Ltd., Budapest, Hungary (S.K.S., I.L.); Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary (K.Á.H.); Metabolic Drug Interactions Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary (M.T.D., Á.F.K., K.M.); Research Centre for Natural Sciences, Instrumentation Center, MS Metabolomic Research Laboratory, Budapest, Hungary (P.T.S.); Department of Biology, MyoKardia Inc., Brisbane, California (S.N., I.T.); Department of Neuroscience, Western New England University, Springfield, Massachusetts (J.K., P.J.T.); and Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary (L.K.) .
Pokaż więcej
Źródło :
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2021 Mar; Vol. 376 (3), pp. 358-373. Date of Electronic Publication: 2021 Jan 19.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Absorption, Physicochemical*
Drug Discovery*
Heterocyclic Compounds, 4 or More Rings/*metabolism
Heterocyclic Compounds, 4 or More Rings/*pharmacology
Myosins/*antagonists & inhibitors
Animals ; Heterocyclic Compounds, 4 or More Rings/chemistry ; Heterocyclic Compounds, 4 or More Rings/toxicity ; Humans ; Molecular Dynamics Simulation ; Myosins/chemistry ; Protein Conformation ; Rats ; Tissue Distribution
Czasopismo naukowe
Tytuł :
Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review.
Autorzy :
Malafaia D; LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, Campus de Santiago, 3810-193, Aveiro, Portugal.
Albuquerque HMT; LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, Campus de Santiago, 3810-193, Aveiro, Portugal. Electronic address: .
Silva AMS; LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, Campus de Santiago, 3810-193, Aveiro, Portugal.
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Mar 15; Vol. 214, pp. 113209. Date of Electronic Publication: 2021 Jan 25.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Alzheimer Disease/*drug therapy
Aminoquinolines/*pharmacology
Amyloid beta-Peptides/*antagonists & inhibitors
Curcumin/*pharmacology
Heterocyclic Compounds, 4 or More Rings/*pharmacology
Tacrine/*pharmacology
tau Proteins/*antagonists & inhibitors
Alzheimer Disease/metabolism ; Aminoquinolines/chemical synthesis ; Aminoquinolines/chemistry ; Amyloid beta-Peptides/metabolism ; Curcumin/chemical synthesis ; Curcumin/chemistry ; Heterocyclic Compounds, 4 or More Rings/chemical synthesis ; Heterocyclic Compounds, 4 or More Rings/chemistry ; Humans ; Molecular Structure ; Structure-Activity Relationship ; Tacrine/chemical synthesis ; Tacrine/chemistry ; tau Proteins/metabolism
Czasopismo naukowe
Tytuł :
Design, Synthesis and Structure-Activity Relationship Studies of Glycosylated Derivatives of Marine Natural Product Lamellarin D.
Autorzy :
Zheng L; Ocean College, Zhejiang University, Zhoushan, 316021, China.
Gao T; Ocean College, Zhejiang University, Zhoushan, 316021, China.
Ge Z; Analysis Center of Agrobiology and Environmental Sciences, Zhejiang University, Hangzhou, 310058, China.
Ma Z; Ocean College, Zhejiang University, Zhoushan, 316021, China.
Xu J; Ocean College, Zhejiang University, Zhoushan, 316021, China.
Ding W; Ocean College, Zhejiang University, Zhoushan, 316021, China.
Shen L; Ocean College, Zhejiang University, Zhoushan, 316021, China. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Mar 15; Vol. 214, pp. 113226. Date of Electronic Publication: 2021 Jan 28.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Design*
Antineoplastic Agents/*pharmacology
Biological Products/*pharmacology
Coumarins/*pharmacology
Heterocyclic Compounds, 4 or More Rings/*pharmacology
Isoquinolines/*pharmacology
Topoisomerase I Inhibitors/*pharmacology
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Biological Products/chemical synthesis ; Biological Products/chemistry ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Coumarins/chemical synthesis ; Coumarins/chemistry ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Glycosylation ; Heterocyclic Compounds, 4 or More Rings/chemical synthesis ; Heterocyclic Compounds, 4 or More Rings/chemistry ; Humans ; Isoquinolines/chemical synthesis ; Isoquinolines/chemistry ; Molecular Structure ; Structure-Activity Relationship ; Topoisomerase I Inhibitors/chemical synthesis ; Topoisomerase I Inhibitors/chemistry ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.
Autorzy :
Fudio S; PharmaMar, Avda. De los Reyes, 1, Pol. Ind. La Mina-Norte, Colmenar Viejo, Madrid, 28770, Spain. .
Tabernero J; Vall d'Hebrón University Hospital and Institute of Oncology (VHIO), 08035, Barcelona, Spain.
Subbiah V; The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Chawla SP; Sarcoma Oncology Center, Santa Monica, CA, 90403, USA.
Moreno V; Fundación Jiménez Díaz, 28040, Madrid, Spain.
Longo F; Hospital Ramon y Cajal, 28034, Madrid, Spain.
Lopez R; IDIS, CIBERONC, Hospital Clínico Universitario de Santiago de Compostela, 15706, Santiago De Compostela, Spain.
Anton A; Hospital Universitario Miguel Servet, 50009, Zaragoza, Spain.
Trigo JM; Hospital Virgen de la Victoria, 29010, Málaga, Spain.
Shapiro G; Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Jeong W; Cancer Therapy and Research Center, San Antonio, TX, 78229, USA.
Villalobos VM; University of Colorado, Denver, CO, 80045, USA.
Lubomirov R; PharmaMar, Avda. De los Reyes, 1, Pol. Ind. La Mina-Norte, Colmenar Viejo, Madrid, 28770, Spain.
Fernandez-Teruel C; PharmaMar, Avda. De los Reyes, 1, Pol. Ind. La Mina-Norte, Colmenar Viejo, Madrid, 28770, Spain.
Alfaro V; PharmaMar, Avda. De los Reyes, 1, Pol. Ind. La Mina-Norte, Colmenar Viejo, Madrid, 28770, Spain.
Boni V; START Madrid-CIOCC, Hospital Universitario San Chinarro, 28050, Madrid, Spain.
Pokaż więcej
Źródło :
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2021 Jan; Vol. 87 (1), pp. 113-124. Date of Electronic Publication: 2020 Oct 27.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*adverse effects
Carbolines/*adverse effects
Heterocyclic Compounds, 4 or More Rings/*adverse effects
Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/pharmacokinetics ; Carbolines/administration & dosage ; Carbolines/pharmacokinetics ; Electrocardiography ; Female ; Heterocyclic Compounds, 4 or More Rings/administration & dosage ; Heterocyclic Compounds, 4 or More Rings/pharmacokinetics ; Humans ; Male ; Middle Aged ; Prospective Studies
Czasopismo naukowe
Tytuł :
A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia.
Autorzy :
Snyder GL; Intra-Cellular Therapies, Inc., The Alexandria Center for Life Science, New York, NY, United States. Electronic address: .
Vanover KE; Intra-Cellular Therapies, Inc., The Alexandria Center for Life Science, New York, NY, United States.
Davis RE; Intra-Cellular Therapies, Inc., The Alexandria Center for Life Science, New York, NY, United States.
Li P; Intra-Cellular Therapies, Inc., The Alexandria Center for Life Science, New York, NY, United States.
Fienberg A; Intra-Cellular Therapies, Inc., The Alexandria Center for Life Science, New York, NY, United States.
Mates S; Intra-Cellular Therapies, Inc., The Alexandria Center for Life Science, New York, NY, United States.
Pokaż więcej
Źródło :
Advances in pharmacology (San Diego, Calif.) [Adv Pharmacol] 2021; Vol. 90, pp. 253-276. Date of Electronic Publication: 2020 Sep 29.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Heterocyclic Compounds, 4 or More Rings/*therapeutic use
Schizophrenia/*drug therapy
Animals ; Antipsychotic Agents/therapeutic use ; Behavior ; Heterocyclic Compounds, 4 or More Rings/adverse effects ; Heterocyclic Compounds, 4 or More Rings/chemistry ; Humans ; Schizophrenia/diagnostic imaging ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Lumateperone: A Novel Antipsychotic for Schizophrenia.
Autorzy :
Greenwood J; Nova Southeastern University, Fort Lauderdale, FL, USA.
Acharya RB; Nova Southeastern University, Fort Lauderdale, FL, USA.
Marcellus V; Nova Southeastern University, Fort Lauderdale, FL, USA.
Rey JA; Nova Southeastern University, Fort Lauderdale, FL, USA.
Pokaż więcej
Źródło :
The Annals of pharmacotherapy [Ann Pharmacother] 2021 Jan; Vol. 55 (1), pp. 98-104. Date of Electronic Publication: 2020 Jun 26.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antipsychotic Agents/*therapeutic use
Heterocyclic Compounds, 4 or More Rings/*therapeutic use
Schizophrenia/*drug therapy
Antipsychotic Agents/administration & dosage ; Antipsychotic Agents/adverse effects ; Antipsychotic Agents/pharmacokinetics ; Heterocyclic Compounds, 4 or More Rings/administration & dosage ; Heterocyclic Compounds, 4 or More Rings/adverse effects ; Heterocyclic Compounds, 4 or More Rings/pharmacokinetics ; Humans ; Randomized Controlled Trials as Topic ; Treatment Outcome ; United States ; United States Food and Drug Administration
Czasopismo naukowe
Tytuł :
Bioinspired Diversification Approach Toward the Total Synthesis of Lycodine-Type Alkaloids.
Autorzy :
Haley HMS; Department of Chemistry, University of California, Berkeley, California 94720, United States.
Payer SE; Department of Chemistry, University of California, Berkeley, California 94720, United States.
Papidocha SM; Department of Chemistry, University of California, Berkeley, California 94720, United States.
Clemens S; Department of Chemistry, University of California, Berkeley, California 94720, United States.
Nyenhuis J; Department of Chemistry, University of California, Berkeley, California 94720, United States.
Sarpong R; Department of Chemistry, University of California, Berkeley, California 94720, United States.
Pokaż więcej
Źródło :
Journal of the American Chemical Society [J Am Chem Soc] 2021 Mar 31; Vol. 143 (12), pp. 4732-4740. Date of Electronic Publication: 2021 Mar 17.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Alkaloids/*chemical synthesis
Heterocyclic Compounds, 4 or More Rings/*chemical synthesis
Alkaloids/chemistry ; Heterocyclic Compounds, 4 or More Rings/chemistry ; Lycopodium/chemistry ; Molecular Structure ; Stereoisomerism
Czasopismo naukowe
Tytuł :
Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.
Autorzy :
Gaudy A; Clinical Pharmacology, Bristol Myers Squibb, Princeton, NJ, USA. .
Atsriku C; Nonclinical Development, Bristol Myers Squibb, Princeton, NJ, USA.
Ye Y; Clinical Pharmacology, Bristol Myers Squibb, Princeton, NJ, USA.
MacGorman K; Clinical Pharmacology, Bristol Myers Squibb, Princeton, NJ, USA.
Liu L; Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, NJ, USA.
Xue Y; Nonclinical Development, Bristol Myers Squibb, Princeton, NJ, USA.
Surapaneni S; Nonclinical Development, Bristol Myers Squibb, Princeton, NJ, USA.
Palmisano M; Clinical Pharmacology, Bristol Myers Squibb, Princeton, NJ, USA.
Pokaż więcej
Źródło :
European journal of clinical pharmacology [Eur J Clin Pharmacol] 2021 Feb; Vol. 77 (2), pp. 223-231. Date of Electronic Publication: 2020 Sep 23.
Typ publikacji :
Clinical Trial, Phase I; Journal Article
MeSH Terms :
Cytochrome P-450 CYP3A Inducers/*pharmacokinetics
Cytochrome P-450 CYP3A Inhibitors/*pharmacokinetics
Heterocyclic Compounds, 4 or More Rings/*pharmacokinetics
Immunologic Factors/*pharmacokinetics
Adult ; Area Under Curve ; Cytochrome P-450 CYP3A/metabolism ; Cytochrome P-450 CYP3A Inducers/administration & dosage ; Cytochrome P-450 CYP3A Inhibitors/administration & dosage ; Drug Interactions ; Female ; Healthy Volunteers ; Heterocyclic Compounds, 4 or More Rings/administration & dosage ; Humans ; Immunologic Factors/administration & dosage ; Itraconazole/administration & dosage ; Itraconazole/pharmacokinetics ; Lupus Erythematosus, Systemic/drug therapy ; Lupus Erythematosus, Systemic/immunology ; Male ; Microsomes, Liver ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/immunology ; Rifampin/administration & dosage ; Rifampin/pharmacokinetics ; Young Adult
Czasopismo naukowe
Tytuł :
Close-up: HIV/SIV intasome structures shed new light on integrase inhibitor binding and viral escape mechanisms.
Autorzy :
Engelman AN; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Cherepanov P; Chromatin Structure and Mobile DNA Laboratory, Francis Crick Institute, London, UK.; Department of Infectious Disease, Imperial College London, St. Mary's Campus, London, UK.
Pokaż więcej
Źródło :
The FEBS journal [FEBS J] 2021 Jan; Vol. 288 (2), pp. 427-433. Date of Electronic Publication: 2020 Jun 22.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Review
MeSH Terms :
HIV Integrase/*chemistry
HIV Integrase Inhibitors/*chemistry
HIV-1/*drug effects
Heterocyclic Compounds, 3-Ring/*chemistry
Heterocyclic Compounds, 4 or More Rings/*chemistry
Oxazines/*chemistry
Piperazines/*chemistry
Pyridones/*chemistry
Simian Immunodeficiency Virus/*drug effects
Animals ; Catalytic Domain ; Cryoelectron Microscopy ; Drug Resistance, Viral/drug effects ; Drug Resistance, Viral/genetics ; HIV Infections/drug therapy ; HIV Infections/virology ; HIV Integrase/genetics ; HIV Integrase/metabolism ; HIV Integrase Inhibitors/pharmacology ; HIV-1/chemistry ; HIV-1/enzymology ; Heterocyclic Compounds, 3-Ring/pharmacology ; Heterocyclic Compounds, 4 or More Rings/pharmacology ; Humans ; Oxazines/pharmacology ; Piperazines/pharmacology ; Protein Binding ; Protein Conformation, alpha-Helical ; Protein Conformation, beta-Strand ; Protein Interaction Domains and Motifs ; Pyridones/pharmacology ; Simian Immunodeficiency Virus/chemistry ; Simian Immunodeficiency Virus/enzymology ; Spumavirus/chemistry ; Spumavirus/drug effects ; Spumavirus/enzymology
Czasopismo naukowe
Tytuł :
Inhibitory potency of 4- substituted sampangine derivatives toward Cu mediated aggregation of amyloid β-peptide, oxidative stress, and inflammation in Alzheimer's disease.
Autorzy :
Su C; State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Guilin City, Guangxi, China.
Chen Y; State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Guilin City, Guangxi, China.
Chen K; State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Guilin City, Guangxi, China.
Li W; State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Guilin City, Guangxi, China.
Tang H; State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Guilin City, Guangxi, China. Electronic address: .
Pokaż więcej
Źródło :
Neurochemistry international [Neurochem Int] 2020 Oct; Vol. 139, pp. 104794. Date of Electronic Publication: 2020 Jul 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Alkaloids/*therapeutic use
Alzheimer Disease/*metabolism
Amyloid beta-Peptides/*toxicity
Copper/*toxicity
Heterocyclic Compounds, 4 or More Rings/*therapeutic use
Naphthyridines/*therapeutic use
Oxidative Stress/*drug effects
Peptide Fragments/*toxicity
Protein Aggregation, Pathological/*metabolism
Alkaloids/chemistry ; Alkaloids/pharmacology ; Alzheimer Disease/drug therapy ; Alzheimer Disease/genetics ; Animals ; Animals, Genetically Modified ; Caenorhabditis elegans ; Cell Line, Tumor ; Heterocyclic Compounds, 4 or More Rings/chemistry ; Heterocyclic Compounds, 4 or More Rings/pharmacology ; Humans ; Mice ; Microglia/drug effects ; Microglia/metabolism ; Naphthyridines/chemistry ; Naphthyridines/pharmacology ; Oxidative Stress/physiology ; Protein Aggregation, Pathological/drug therapy ; Protein Aggregation, Pathological/genetics
Czasopismo naukowe
Tytuł :
Gymnodimine A and 13-desMethyl Spirolide C Alter Intracellular Calcium Levels via Acetylcholine Receptors.
Autorzy :
Nieva JA; Alfred Wegener Institute, Helmholtz Center for Polar and Marine Research, D-27570 Bremerhaven, Germany.
Krock B; Alfred Wegener Institute, Helmholtz Center for Polar and Marine Research, D-27570 Bremerhaven, Germany.
Tillmann U; Alfred Wegener Institute, Helmholtz Center for Polar and Marine Research, D-27570 Bremerhaven, Germany.
Tebben J; Alfred Wegener Institute, Helmholtz Center for Polar and Marine Research, D-27570 Bremerhaven, Germany.
Zurhelle C; Alfred Wegener Institute, Helmholtz Center for Polar and Marine Research, D-27570 Bremerhaven, Germany.
Bickmeyer U; Alfred Wegener Institute, Helmholtz Center for Polar and Marine Research, D-27570 Bremerhaven, Germany.
Pokaż więcej
Źródło :
Toxins [Toxins (Basel)] 2020 Nov 27; Vol. 12 (12). Date of Electronic Publication: 2020 Nov 27.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Calcium/*metabolism
Heterocyclic Compounds, 4 or More Rings/*pharmacology
Imines/*pharmacology
Receptors, Muscarinic/*metabolism
Receptors, Nicotinic/*metabolism
Spiro Compounds/*pharmacology
Animals ; Calcium Channels/metabolism ; Calcium Signaling/drug effects ; Cell Line ; Dinoflagellida/metabolism ; Heterocyclic Compounds, 4 or More Rings/isolation & purification ; Imines/isolation & purification ; Marine Toxins/isolation & purification ; Marine Toxins/pharmacology ; Muscarinic Antagonists ; Nicotinic Agonists ; PC12 Cells ; Rats ; Spiro Compounds/isolation & purification
Czasopismo naukowe
Tytuł :
DNA damage induced by KP372-1 hyperactivates PARP1 and enhances lethality of pancreatic cancer cells with PARP inhibition.
Autorzy :
Viera T; Department of Chemistry, New Mexico Institute of Mining and Technology, 801 Leroy Pl, Socorro, NM, 87801, USA.
Patidar PL; Department of Chemistry, New Mexico Institute of Mining and Technology, 801 Leroy Pl, Socorro, NM, 87801, USA. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Nov 19; Vol. 10 (1), pp. 20210. Date of Electronic Publication: 2020 Nov 19.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antineoplastic Agents/*pharmacology
Cell Survival/*drug effects
DNA Damage/*drug effects
Heterocyclic Compounds, 4 or More Rings/*pharmacology
Pancreatic Neoplasms/*drug therapy
Poly (ADP-Ribose) Polymerase-1/*metabolism
Tetrazoles/*pharmacology
Antineoplastic Agents/therapeutic use ; Cell Death/drug effects ; Cell Line, Tumor ; Heterocyclic Compounds, 4 or More Rings/therapeutic use ; Humans ; NAD(P)H Dehydrogenase (Quinone)/metabolism ; Pancreatic Neoplasms/metabolism ; Pancreatic Neoplasms/pathology ; Reactive Oxygen Species/metabolism ; Tetrazoles/therapeutic use
Czasopismo naukowe
Tytuł :
Placental transfer of the integrase strand inhibitors cabotegravir and bictegravir in the ex-vivo human cotyledon perfusion model.
Autorzy :
Pencolé L; AP-HP, Hôpital Louis Mourier, Service de Gynécologie-Obstétrique, Colombes.
Lê MP; AP-HP, Hôpital Bichat-Claude Bernard, Laboratoire de Pharmacologie-Toxicologie.; INSERM, UMRS 1144, Université de Paris.; INSERM, IAME, UMR 1137 Université de Paris, Paris, France.
Bouchet-Crivat F; INSERM, IAME, UMR 1137 Université de Paris, Paris, France.
Duro D; AP-HP, Hôpital Louis Mourier, Service de Gynécologie-Obstétrique, Colombes.
Peytavin G; AP-HP, Hôpital Bichat-Claude Bernard, Laboratoire de Pharmacologie-Toxicologie.; INSERM, IAME, UMR 1137 Université de Paris, Paris, France.
Mandelbrot L; AP-HP, Hôpital Louis Mourier, Service de Gynécologie-Obstétrique, Colombes.; INSERM, IAME, UMR 1137 Université de Paris, Paris, France.
Pokaż więcej
Źródło :
AIDS (London, England) [AIDS] 2020 Nov 15; Vol. 34 (14), pp. 2145-2149.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
HIV Infections*/drug therapy
Maternal-Fetal Exchange*
Cotyledon/*metabolism
HIV Integrase Inhibitors/*therapeutic use
Heterocyclic Compounds, 4 or More Rings/*pharmacokinetics
Placenta/*metabolism
Pyridones/*pharmacokinetics
Female ; Fetus/blood supply ; Heterocyclic Compounds, 4 or More Rings/therapeutic use ; Humans ; In Vitro Techniques ; Models, Biological ; Perfusion ; Placenta/blood supply ; Pregnancy ; Pyridones/therapeutic use
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies